BIO101 in Obesity

A unique program to protect muscle during weight loss

A unique program to protect muscle during weight loss

Medical Need:

Obesity affects more than 1 billion people worldwide, 96% of whom report mobility problems.

In recent years, anti-obesity medications have revolutionized obesity management, delivering unprecedented weight loss. However, they face a critical challenge: fat reduction is accompanied by significant loss of lean muscle mass.

No approved therapy currently exists that can protect muscle mass during obesity management.

Preclinical results:

A four-week study combining BIO101 with a GLP-1 receptor agonist in diet-induced obese mice showed encouraging results:

  • Improved locomotor activity and grip strength in animals versus the untreated group
  • The drug combination compensates for alterations in muscle contractile force

OBA Phase II trial design:

This clinical study will focus on muscle mass in obesity management.

  • Target indication: as an adjunct to GLP-1 receptor agonists, to reduce muscle mass loss caused by GLP-1 therapy and dieting in overweight and obese adults
  • Target population: 164 obese patients with one or more weight-related comorbidities, initiating treatment with semaglutide (a GLP-1 agonist)
  • Primary endpoint: muscle strength measured by knee extension (dynamometry)